Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

Shipments to China are now paused through the end of 2025, dragging global sales of the HPV vaccine down 55% last quarter.

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

MSD – known as Merck & Co in the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has been ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug ...

Keytruda is certainly established as one of the most formidable cancer therapies, setting an exceptionally high bar. Launching in 2014, the drug raked in a mind-boggling $42.65 billion (PDF) from ...

Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and ...

Patients whose PD-L1 levels were above 50% — those for whom Keytruda already has the FDA’s blessing — survived a median of 20 months with Keytruda, compared with 12.2 months for chemotherapy.

Merck’s (NYSE:MRK) Keytruda is its top selling drug with sales of over $7 billion in 2018. Keytruda is used for the treatment of different types of cancers, including lung, head & neck, and ...